Stock Scorer

Outlook Therapeutics, Inc. (OTLK)

Outlook Therapeutics, Inc. reported revenue of 1.5M USD for the quarter ending 30 June 2025, up 41.0% from 1.1M a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 09-30. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '25 · ending 30 June 2025 1.5M +41.0%
Gross Profit Q2 '26 · ending 30 June 2026 -8.3K —
Operating Income Q2 '26 · ending 30 June 2026 -10.8M —
Net Income Q2 '26 · ending 30 June 2026 -20.3M —
Cost of Revenue Q2 '26 · ending 30 June 2026 17K -96.1%
Operating Cash Flow Q2 '26 · ending 30 June 2026 -21M —
Free Cash Flow Q3 '19 · ending 30 September 2019 -5.9M —
Shares Outstanding Q2 '26 · ending 30 June 2026 136.7M +342.9%
EPS Q2 '26 · ending 30 June 2026 -0.77 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-09-30 1.4M-67.1M-62.4M—
20192019-09-30 8.1M-36.3M-34.5M-32.7M
20182018-09-30 3.1M-29.6M-30.1M-35.8M
20172017-09-30 3.8M-35.9M-38.8M-15.8M
20162016-09-30 3M-51.3M-53.3M-46.6M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q3 '252025-06-301.5M
Q4 '192019-09-305.9M
Q3 '192019-06-30583.8K
Q2 '192019-03-31641.1K
Q1 '192018-12-311.1M
Q4 '182018-09-30771.9K
Q3 '182018-06-30771.9K
Q2 '182018-03-31771.9K
Q1 '182017-12-31771.9K
Q4 '172017-09-302.9M
Q3 '172017-06-30303.1K
Q2 '172017-03-31303.1K
Q1 '172016-12-31303.1K
Q4 '162016-09-30494.9K
Q3 '162016-06-30494.9K
Q2 '162016-03-31994.9K
Q1 '162015-12-31994.9K
Q4 '152015-09-30494.9K
Q3 '152015-06-301.3M
Q2 '152015-03-31494.9K

Gross Profit Quarterly

PeriodEndingGross Profit
Q3 '262026-06-30-8.3K
Q2 '262026-03-31-21.9K
Q1 '262025-12-31-1.2M
Q3 '252025-06-301.1M

Operating Income Quarterly

PeriodEndingOperating Income
Q3 '262026-06-30-10.8M
Q2 '262026-03-31-14M
Q1 '262025-12-31-13.5M
Q4 '252025-09-30-17.3M
Q3 '252025-06-30-15.7M
Q2 '252025-03-31-12.4M
Q1 '252024-12-31-21.6M
Q4 '242024-09-30-22.9M
Q3 '242024-06-30-19.6M
Q2 '242024-03-31-18.9M
Q1 '242023-12-31-10.3M
Q4 '232023-09-30-12.5M
Q3 '232023-06-30-18.1M
Q2 '232023-03-31-6.8M
Q1 '232022-12-31-15.7M
Q4 '222022-09-30-14M
Q3 '222022-06-30-17M
Q2 '222022-03-31-18.9M
Q1 '222021-12-31-13.1M
Q4 '212021-09-30-13.4M

Net Income Quarterly

PeriodEndingNet Income
Q3 '262026-06-30-20.3M
Q2 '262026-03-31-4.5M
Q1 '262025-12-31-23.1M
Q4 '252025-09-30-13.3M
Q3 '252025-06-30-20.2M
Q2 '252025-03-31-46.4M
Q1 '252024-12-3117.4M
Q4 '242024-09-305.7M
Q3 '242024-06-3044.4M
Q2 '242024-03-31-114.3M
Q1 '242023-12-31-11.2M
Q4 '232023-09-30-13M
Q3 '232023-06-30-20.7M
Q2 '232023-03-31-6.7M
Q1 '232022-12-31-18.7M
Q4 '222022-09-30-14.3M
Q3 '222022-06-30-17.5M
Q2 '222022-03-31-19.7M
Q1 '222021-12-31-14.5M
Q4 '212021-09-30-13.4M

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q3 '262026-06-3017K
Q2 '262026-03-31149.3K
Q1 '262025-12-3129.6K
Q4 '252025-09-30916.5K
Q3 '252025-06-30439.8K

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q3 '262026-06-30-21M
Q2 '262026-03-31-7.8M
Q1 '262025-12-31-14.9M
Q4 '252025-09-30-12.4M
Q3 '252025-06-30-11.9M
Q2 '252025-03-31-16.6M
Q1 '252024-12-31-11M
Q4 '242024-09-30-17M
Q3 '242024-06-30-19.5M
Q2 '242024-03-31-19.3M
Q1 '242023-12-31-13M
Q4 '232023-09-30-12.7M
Q3 '232023-06-30-13.2M
Q2 '232023-03-31-8.1M
Q1 '232022-12-31-8.9M
Q4 '222022-09-30-10.3M
Q3 '222022-06-30-21.1M
Q2 '222022-03-31-14.3M
Q1 '222021-12-31-11M
Q4 '212021-09-30-9M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q4 '192019-09-30-5.9M
Q3 '192019-06-30-10.5M
Q2 '192019-03-31-6.3M
Q1 '192018-12-31-10M
Q4 '182018-09-30-9.7M
Q3 '182018-06-30-8.7M
Q2 '182018-03-31-7.7M
Q1 '182017-12-31-9.7M
Q4 '172017-09-3055.9K
Q3 '172017-06-30-5.7M
Q2 '172017-03-31-4.2M
Q1 '172016-12-31-6M
Q4 '162016-09-30-10.7M
Q3 '162016-06-30-16.5M
Q2 '162016-03-31-7.1M
Q1 '162015-12-31-12.4M
Q4 '152015-09-30-14.3M
Q3 '152015-06-30-13.5M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q3 '262026-06-30136.7M
Q2 '262026-03-3181.8M
Q1 '262025-12-3160.2M
Q3 '252025-06-3037M
Q2 '252025-03-3130.9M
Q1 '252024-12-3124.2M
Q3 '242024-06-3025.5M
Q2 '242024-03-3114.3M
Q1 '242023-12-3113M
Q3 '232023-06-3012.8M
Q2 '232023-03-3112.8M
Q1 '232022-12-31227.4M
Q3 '222022-06-30220.5M
Q2 '222022-03-31219.1M
Q1 '222021-12-31188.2M
Q3 '212021-06-30168.4M
Q2 '212021-03-31150.7M
Q1 '212020-12-31121.7M
Q3 '202020-06-3090.8M
Q3 '182018-06-3034.5M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q3 '262026-06-30-0.77
Q2 '262026-03-31-1.17
Q1 '262025-12-31-2.62
Q4 '252025-09-30-1.52
Q3 '242024-06-30-10.75
Q2 '242024-03-31-11.47
Q1 '242023-12-31-3.98
Q4 '232023-09-30-3.20
Q3 '232023-06-30-2.27
Q2 '232023-03-31-0.74
Q1 '232022-12-31-0.31
Q4 '222022-09-30-0.31
Q3 '222022-06-30-0.33
Q2 '222022-03-31-0.32
Q1 '222021-12-31-0.32
Q4 '212021-09-30-0.36
Q3 '212021-06-30-0.26
Q2 '212021-03-31-0.22
Q1 '212020-12-31-0.49
Q4 '202020-09-30-0.99